USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway.
about
Cloning and characterization of the human USP22 gene promoterEpigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancerUSP22 maintains gastric cancer stem cell stemness and promotes gastric cancer progression by stabilizing BMI1 proteinUSP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway.USP22 is useful as a novel molecular marker for predicting disease progression and patient prognosis of oral squamous cell carcinomaPrognostic Impact of del(17p) and del(22q) as assessed by interphase FISH in sporadic colorectal carcinomas.USP22 promotes NSCLC tumorigenesis via MDMX up-regulation and subsequent p53 inhibition.Ubiquitin-specific peptidase 22, a histone deubiquitinating enzyme, is a novel poor prognostic factor for salivary adenoid cystic carcinoma.Never in mitosis gene A related kinase-6 attenuates pressure overload-induced activation of the protein kinase B pathway and cardiac hypertrophyHigh USP22 expression indicates poor prognosis in hepatocellular carcinoma.Usp22 deficiency impairs intestinal epithelial lineage specification in vivoOverexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancerRNA interference-mediated USP22 gene silencing promotes human brain glioma apoptosis and induces cell cycle arrest.Targeting ubiquitin-specific protease 22 suppresses growth and metastasis of anaplastic thyroid carcinoma.MiR-101 targets USP22 to inhibit the tumorigenesis of papillary thyroid carcinomaA portrayal of E3 ubiquitin ligases and deubiquitylases in cancer.Functions of SAGA in development and disease.Regulation of pluripotency and differentiation by deubiquitinating enzymes.ShRNA-mediated silencing of the ubiquitin-specific protease 22 gene restrained cell progression and affected the Akt pathway in nasopharyngeal carcinomaTargeting Deubiquitinating Enzymes in Glioblastoma Multiforme: Expectations and Challenges.USP22 regulates oncogenic signaling pathways to drive lethal cancer progression.Identification of deubiquitinase targets of isothiocyanates using SILAC-assisted quantitative mass spectrometry.Ubiquitin Specific Peptidase 22 Regulates Histone H2B Mono-Ubiquitination and Exhibits Both Oncogenic and Tumor Suppressor Roles in Cancer.miR-218 inhibits acute promyelocytic leukemia cell growth by targeting BMI-1.Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics.Role of endogenous and exogenous nitric oxide, carbon monoxide and hydrogen sulfide in HCT116 colon cancer cell proliferation.Downregulation of MiR-203a Disinhibits Bmi1 and Promotes Growth and Proliferation of Keratinocytes in Cholesteatoma.Ubiquitin-specific protease 22 acts as an oncoprotein to maintain glioma malignancy through deubiquitinating B cell-specific Moloney murine leukemia virus integration site 1 for stabilization.Ubiquitin-specific protease 22: a novel molecular biomarker in glioma prognosis and therapeutics.
P2860
Q21133783-66919692-8B20-4685-9551-F15D37ED5654Q27022720-5AB36F0C-58D9-4040-98AF-9508E12763C1Q33779463-A142D843-03D3-4118-9807-313D454AB4C4Q33787348-4B12B8B4-3903-4729-9B48-B7B58A8401F5Q34374287-D1114CD7-0CAC-4C98-8C33-D7E14956B967Q34388828-E7D35872-B8CB-4114-844D-DFCDD245566CQ35016431-07C86AE5-F399-4E67-BA97-AA1529470852Q35086256-6577F552-6990-484B-AF32-489E3085082EQ35157232-6EED07D9-CEDB-4C8D-9E3D-BE41089288CBQ35828647-1FA5E849-FF13-4808-9F1A-3680DFF03250Q36545916-A718CB87-5E5A-47BD-9B0C-D2EC7C60128CQ36596567-BCF5A43C-F513-44BE-94F4-94EC247C7D96Q36774604-0674E080-CBE7-4F58-ABF9-B7E13E6A8F24Q37327698-DD2BD164-0CCE-42C1-9DCC-AA9AAAFABD3CQ37447904-3D5AC6D7-2004-467F-B78B-F95AEE07522EQ38084210-A58B568F-441D-48EA-A230-E28C6D8BB4EAQ38238829-B3EDFE11-1A6D-4CA0-8899-67F709B22522Q38855269-A078F876-22C8-4BC4-8658-1468E0BAC0FAQ38931451-3D3C63BD-1238-4337-BD2D-157597E74B95Q38989377-79EAA63C-7F5E-42CF-9154-5F169EB99EA3Q39066491-5DF15B9D-A530-4C13-851E-F4AD1282BB09Q41612750-A086D298-6EEF-4FBC-B8FE-C3131873D795Q47359149-42A77B4E-69DB-4675-A320-A70965E7B617Q47552128-21815A27-A565-4A36-BCE5-6B2BD0C004B7Q47692790-7822F679-7834-4CAB-9C6F-66B65769B2F5Q47711103-EA9A1030-5934-4D1C-8A39-A13F62F3C089Q55410595-9F7BA4C0-5B5C-4603-9BEC-7C65E3915233Q55457011-47967405-40D6-4238-9F54-EB5B28B61994Q55461129-00E75F57-C941-40DC-B18A-DEA16ACAD7E1
P2860
USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
USP22 acts as an oncogene by t ...... a/ARF pathway and Akt pathway.
@en
USP22 acts as an oncogene by t ...... a/ARF pathway and Akt pathway.
@nl
type
label
USP22 acts as an oncogene by t ...... a/ARF pathway and Akt pathway.
@en
USP22 acts as an oncogene by t ...... a/ARF pathway and Akt pathway.
@nl
prefLabel
USP22 acts as an oncogene by t ...... a/ARF pathway and Akt pathway.
@en
USP22 acts as an oncogene by t ...... a/ARF pathway and Akt pathway.
@nl
P2093
P2860
P1476
USP22 acts as an oncogene by t ...... a/ARF pathway and Akt pathway.
@en
P2093
Jing-Lei Liu
Shi-Xiong Jiang
Xi-Shan Wang
Yan-Long Liu
Yan-Mei Yang
P2860
P2888
P304
P356
10.1007/S12013-011-9287-0
P577
2012-01-01T00:00:00Z